(Q38079194)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

review article

1 reference

title

Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

invasive fungal infections

23 February 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Carlos Meneses Oliveira

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

1 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

Clinical Drug Investigation

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

33 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

S5-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Patients at high risk of invasive fungal infections: when and how to treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

New options for treatment of candidaemia in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Liposomal amphotericin B: what is its role in 2008?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Amphotericin B lipid preparations: what are the differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

In-vitro activities of terbinafine, itraconazole and amphotericin B against Aspergillus and Cladosporium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Comparison of lipid amphotericin B preparations in treating murine zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Invasive aspergillosis: diagnosis, prophylaxis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Lipid formulations of amphotericin B as first-line treatment of zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Epidemiology of invasive candidiasis: a persistent public health problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Attributable mortality of nosocomial candidemia, revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Pharmacology of Systemic Antifungal Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-012-0023-3

Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease

21 January 2018

1 reference

12 December 2020

Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group

1 reference

12 December 2020

New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis

1 reference

12 December 2020

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

12 December 2020

Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis

1 reference

12 December 2020

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

12 December 2020

Liposomal amphotericin B treatment for neonatal fungal infections

1 reference

12 December 2020

Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning

1 reference

12 December 2020

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

12 December 2020

Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay

1 reference

12 December 2020

Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer

1 reference

12 December 2020

In vitro activity of five antifungal agents against clinical isolates of Saccharomyces cerevisiae

1 reference

12 December 2020

Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients

1 reference

12 December 2020

Mucormycosis in hematologic malignancies: an emerging fungal infection

1 reference

12 December 2020

Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis

1 reference

12 December 2020

10.1007/S40261-012-0023-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23381977%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference